Clinical Trial Update: Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of bortezomib and rituximab for Non-Hodgkin lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Velcade (bortezomib)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Lymphoma | Phase 2 | Status: COMPLETED